Clemons and colleagues [73] showed that the novel protein arginine methyltransferase 4 (PRMT4) enzyme and ADMA (its downstream product) played a pathological role influencing cerebral blood flow (CBF) in AD. This evidence concerns the gene CARM1 and Alzheimer disease.